Gilead Sciences, Inc. (ETR:GIS)
92.20
0.00 (0.00%)
Jun 25, 2025, 9:27 AM CET
Gilead Sciences Revenue
Gilead Sciences had revenue of $6.67B USD in the quarter ending March 31, 2025, a decrease of -0.28%. This brings the company's revenue in the last twelve months to $28.74B, up 4.68% year-over-year. In the year 2024, Gilead Sciences had annual revenue of $28.75B with 6.04% growth.
Revenue (ttm)
$28.74B
Revenue Growth
+4.68%
P/S Ratio
4.31
Revenue / Employee
$1.63M
Employees
17,600
Market Cap
114.67B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 28.75B | 1.64B | 6.04% |
Dec 31, 2023 | 27.12B | -165.00M | -0.60% |
Dec 31, 2022 | 27.28B | -24.00M | -0.09% |
Dec 31, 2021 | 27.31B | 2.62B | 10.60% |
Dec 31, 2020 | 24.69B | 2.24B | 9.98% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.14B |
Merck KGaA | 21.32B |
Bayer Aktiengesellschaft | 46.58B |
Fresenius SE & Co. KGaA | 22.13B |
Fresenius Medical Care AG | 19.49B |
Sartorius Aktiengesellschaft | 3.44B |
Carl Zeiss Meditec AG | 2.17B |
Fielmann Group AG | 2.33B |
Gilead Sciences News
- 1 day ago - Gilead Sciences - Born With HIV in the 80s: Kim's Story of Growing Up as a Dandelion - Wallstreet:Online
- 1 day ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD - GlobeNewsWire
- 2 days ago - Gilead Sciences CEO on FDA approval of Yeztugo: A milestone moment in the history of HIV - CNBC
- 2 days ago - Watch CNBC's full interview with Gilead Sciences chairman and CEO Daniel ODay - CNBC
- 2 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD - PRNewsWire
- 5 days ago - FDA Approves Gilead's 'Game Changing' Twice-Yearly Shot To Prevent HIV Transmission, Critics Slam $28K Price Tag - Benzinga
- 6 days ago - FDA approves first twice-yearly injection that prevents HIV infection - Fox News
- 6 days ago - U.S. approves twice-a-year shot to prevent HIV but cuts to public health and foreign aid cloud its prospects - Fortune